The Experts below are selected from a list of 36105 Experts worldwide ranked by ideXlab platform
Ronald C. Montelaro - One of the best experts on this subject based on the ideXlab platform.
-
replication of equine infectious anemia virus in engineered mouse nih 3t3 cells
Journal of Virology, 2009Co-Authors: Baoshan Zhang, Ronald C. MontelaroAbstract:We employed the equine Lentivirus equine infectious anemia virus (EIAV) to investigate the cellular restrictions for Lentivirus replication in murine NIH 3T3 cells. The results of these studies demonstrate that NIH 3T3 cells expressing the EIAV receptor ELR1 and equine cyclin T1 supported productive replication of EIAV and produced infectious virions at levels similar to those found in a reference permissive equine cell line. The studies presented here demonstrate, for the first time, differential levels of restriction for EIAV and human immunodeficiency virus type 1 (HIV-1) replication in murine cells and suggest that these differences can be exploited to reveal critical virus-cell interactions required for HIV-1 assembly and budding of Lentivirus particles.
-
equine infectious anemia virus eiav what has hiv s country cousin got to tell us
Veterinary Research, 2004Co-Authors: Caroline Leroux, Jeanluc Cadore, Ronald C. MontelaroAbstract:Equine Infectious Anemia Virus (EIAV) is a Lentivirus, of the Retrovirus family, with an almost worldwide distribution, infecting equids. It causes a persistent infection characterized by recurring febrile episodes associating viremia, fever, thrombocytopenia, and wasting symptoms. The disease is experimentally reproducible by inoculation of Shetland ponies or horses with EIAV pathogenic strains. Among Lentiviruses, EIAV is unique in that, despite a rapid virus replication and antigenic variation, most animals progress from a chronic stage characterized by recurring peaks of viremia and fever to an asymptomatic stage of infection. The inapparent carriers remain infective for life, as demonstrated by experimental transfer of blood to naive animals. The understanding of the correlates of this immune control is of great interest in defining vaccine strategies. Research on EIAV, this "country cousin" of HIV (Human Immunodeficiency Virus), over the last five decades has produced some interesting results on natural immunological control of Lentivirus replication and disease and on the nature and role of virus variation in persistence and pathogenesis. These studies are of interest in the context of HIV and efforts to develop a vaccine. This review will focus on some of the most recent results. equine infectious anemia virus / Lentivirus / equids / vaccine / viral evolution
Robert H Mealey - One of the best experts on this subject based on the ideXlab platform.
-
antibody escape kinetics of equine infectious anemia virus infection of horses
Journal of Virology, 2015Co-Authors: Elissa J. Schwartz, Seema Nanda, Robert H MealeyAbstract:Lentivirus escape from neutralizing antibodies (NAbs) is not well understood. In this work, we quantified antibody escape of a Lentivirus, using antibody escape data from horses infected with equine infectious anemia virus. We calculated antibody blocking rates of wild-type virus, fitness costs of mutant virus, and growth rates of both viruses. These quantitative kinetic estimates of antibody escape are important for understanding lentiviral control by antibody neutralization and in developing NAb-eliciting vaccine strategies.
-
protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency
Journal of Virology, 2011Co-Authors: Sandra D Taylor, Steven R Leib, Wuwei Wu, Robert Nelson, Susan Carpenter, Robert H MealeyAbstract:Using the equine infectious anemia virus (EIAV) Lentivirus model system, we previously demonstrated protective effects of broadly neutralizing immune plasma in young horses (foals) with severe combined immunodeficiency (SCID). However, in vivo selection of a neutralization-resistant envelope variant occurred. Here, we determined the protective effects of purified immunoglobulin with more potent broadly neutralizing activity. Overall, protection correlated with the breadth and potency of neutralizing activity in vitro. Four of five SCID foals were completely protected against homologous challenge, while partial protection occurred following heterologous challenge. These results support the inclusion of broadly neutralizing antibodies in Lentivirus control strategies.
Jeanluc Cadore - One of the best experts on this subject based on the ideXlab platform.
-
equine infectious anemia virus eiav what has hiv s country cousin got to tell us
Veterinary Research, 2004Co-Authors: Caroline Leroux, Jeanluc Cadore, Ronald C. MontelaroAbstract:Equine Infectious Anemia Virus (EIAV) is a Lentivirus, of the Retrovirus family, with an almost worldwide distribution, infecting equids. It causes a persistent infection characterized by recurring febrile episodes associating viremia, fever, thrombocytopenia, and wasting symptoms. The disease is experimentally reproducible by inoculation of Shetland ponies or horses with EIAV pathogenic strains. Among Lentiviruses, EIAV is unique in that, despite a rapid virus replication and antigenic variation, most animals progress from a chronic stage characterized by recurring peaks of viremia and fever to an asymptomatic stage of infection. The inapparent carriers remain infective for life, as demonstrated by experimental transfer of blood to naive animals. The understanding of the correlates of this immune control is of great interest in defining vaccine strategies. Research on EIAV, this "country cousin" of HIV (Human Immunodeficiency Virus), over the last five decades has produced some interesting results on natural immunological control of Lentivirus replication and disease and on the nature and role of virus variation in persistence and pathogenesis. These studies are of interest in the context of HIV and efforts to develop a vaccine. This review will focus on some of the most recent results. equine infectious anemia virus / Lentivirus / equids / vaccine / viral evolution
Caroline Leroux - One of the best experts on this subject based on the ideXlab platform.
-
equine infectious anemia virus eiav what has hiv s country cousin got to tell us
Veterinary Research, 2004Co-Authors: Caroline Leroux, Jeanluc Cadore, Ronald C. MontelaroAbstract:Equine Infectious Anemia Virus (EIAV) is a Lentivirus, of the Retrovirus family, with an almost worldwide distribution, infecting equids. It causes a persistent infection characterized by recurring febrile episodes associating viremia, fever, thrombocytopenia, and wasting symptoms. The disease is experimentally reproducible by inoculation of Shetland ponies or horses with EIAV pathogenic strains. Among Lentiviruses, EIAV is unique in that, despite a rapid virus replication and antigenic variation, most animals progress from a chronic stage characterized by recurring peaks of viremia and fever to an asymptomatic stage of infection. The inapparent carriers remain infective for life, as demonstrated by experimental transfer of blood to naive animals. The understanding of the correlates of this immune control is of great interest in defining vaccine strategies. Research on EIAV, this "country cousin" of HIV (Human Immunodeficiency Virus), over the last five decades has produced some interesting results on natural immunological control of Lentivirus replication and disease and on the nature and role of virus variation in persistence and pathogenesis. These studies are of interest in the context of HIV and efforts to develop a vaccine. This review will focus on some of the most recent results. equine infectious anemia virus / Lentivirus / equids / vaccine / viral evolution
Elissa J. Schwartz - One of the best experts on this subject based on the ideXlab platform.
-
antibody escape kinetics of equine infectious anemia virus infection of horses
Journal of Virology, 2015Co-Authors: Elissa J. Schwartz, Seema Nanda, Robert H MealeyAbstract:Lentivirus escape from neutralizing antibodies (NAbs) is not well understood. In this work, we quantified antibody escape of a Lentivirus, using antibody escape data from horses infected with equine infectious anemia virus. We calculated antibody blocking rates of wild-type virus, fitness costs of mutant virus, and growth rates of both viruses. These quantitative kinetic estimates of antibody escape are important for understanding lentiviral control by antibody neutralization and in developing NAb-eliciting vaccine strategies.